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Background. Angiotensin II type 2 receptor–deficient mice
(AT2−/y) provide an opportunity to study the relationship be-
tween the angiotensin II type 1 receptor (AT1) and nitric oxide
synthase (NOS) isoforms without concomitant AT2 receptor–
related effects. To test this relationship, the expression of renal
NOS isoforms (neural, inducible, and endothelial) in AT2−/y
and AT2+/y mice was examined. The mice were challenged
with deoxycorticosterone acetate (DOCA)-salt to stimulate NO
generation.
Methods. Gene expression analyses by real-time polymerase
chain reaction (PCR) (TaqMan) were performed in kidneys
to characterize neuronal nitric oxide synthase (nNOS), ep-
ithelial nitric oxide synthase (eNOS), inducible nitric oxide
synthase (iNOS), and the AT1 receptor. Pressure-natriuresis ex-
periments were done to determine the physiologic background.
Results. AT2−/y mice showed nNOS and iNOS up-
regulation. DOCA-salt increased iNOS expression more in
AT2−/y mice than in AT2+/y mice. Immunohistochemistry lo-
calized the iNOS expression with DOCA-salt mainly in the
glomeruli. eNOS was not different between the groups, and was
not affected by DOCA-salt. DOCA-salt increased mean arte-
rial pressure more in AT2−/y mice than in AT2+/y mice. Con-
comitantly, the pressure-natriuresis relationship was shifted to
the right in AT2−/y and AT2+/y mice after DOCA-salt. DOCA-
salt decreased renal blood flow (RBF) and glomerular filtration
rate (GFR) in both groups. iNOS blockade did not lower blood
pressure.
Conclusion. We conclude that AT2 receptor deletion and con-
comitant up-regulation of the AT1 receptor is associated with
up-regulation of nNOS and iNOS. Under DOCA-salt, renal
iNOS expression was further increased. Because iNOS inhibi-
tion did not change blood pressure, iNOS may not be involved
in the hemodynamics, but may contribute to organ damage.
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The renin-angiotensin system has close inter-
relationships with nitric oxide (NO) generation.
Both are highly important in regulating renal function
and maintaining sodium and water balance; both are
important for regulation of blood pressure through extra-
cellular fluid volume control. The effects of angiotensin
(Ang) II are mediated by at least two receptor isoforms
(AT1 and AT2). Through stimulation of aldosterone,
Ang II enhances sodium reabsorption indirectly. On the
other hand, the stimulation of the AT2 receptor may
serve a counter-regulatory protective role in response
to the AT1 receptor–dependent effects [1, 2]. In mice
lacking the AT2 receptor, renal blood flow (RBF) and
glomerular filtration rate (GFR) are reduced, causing a
shift to the right in pressure natriuresis and diuresis [3].
NO is released within the kidney and participates in
the control of renal and glomerular hemodynamics, tubu-
loglomerular feedback, and renin release to influence
sodium and water excretion [4]. We showed earlier that
in mice lacking the AT2 receptor, L-NAME–induced re-
nal and blood pressure effects are aggravated, and that
AT1 receptor blockade prevents blood pressure increase
[5]. This study indicated that the AT1 receptor plays a
major role in L-NAME-dependent hypertension. In a
recent in vitro study [6], evidence was presented that
the AT2 receptor attenuates Ang II–induced vessel con-
traction via the AT1 receptor by an NO-related mech-
anism. The authors suggested that NO counteracts AT1
receptor–dependent Ang II effects. The AT1 receptor is
up-regulated in AT2−/y mice [3, 7, 8]. Thus, the AT2−/y
mouse should be suitable to allow studying the unop-
posed AT1 receptor effects on NOS isoform expression
in the kidney, the organ which is responsible for long-
term blood pressure regulation. We suspected that NOS
isoforms might actually be down-regulated in mice miss-
ing the AT2 receptor. To test this notion, we character-
ized the expression of eNOS, iNOS, and nNOS in the
kidneys of AT2−/y and AT2+/y mice. We challenged the
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mice with DOCA-salt to stimulate NO generation. To
provide physiologic background information, we studied
blood pressure changes and renal functions in these mice.
Finally, we studied blood pressures in DOCA-salt mice
under iNOS blockade with guanidinoethyldisulfide 2HCl
(GED) to test the relevance of DOCA-salt dependent
iNOS up-regulation on blood pressure.
METHODS
All animals were obtained from breeder pairs sup-
plied by the Vanderbilt University Medical Center
(Nashville, TN, USA) courtesy of Dr. T. Inagami. The
mice were allowed free access to standard chow (0.25%
sodium, SNIFF Spezialita¨ten; GmbH, Soest, Germany)
and drinking water ad libitum. The experimental proto-
col was approved by the local council on animal care,
whose standards correspond to those of the American
Physiological Society. Genotypes were verified by poly-
merase chain reaction (PCR). For the experiments, we
used only male mice. The body weights of the mice aver-
aged 30.7 ± 0.4 g (AT2+/y), 26.3 ± 0.5 g (AT2−/y), 31.3 ±
0.6 g (AT2+/y and DOCA-salt), 26.8 ± 0.5 g (AT2−/y
and DOCA-salt), 29.2 ± 1.2 g (AT2+/y and DOCA-salt/
GED), and 24.9 ± 0.8 g (AT2−/y and DOCA-salt/GED).
Expression analyses
Gene expression analyses of the isoforms (nNOS,
eNOS, iNOS) of the NO system (N = 7) and the re-
nal AT1 receptor (N = 10) were performed in kidneys
of each group (AT2+/y, AT2−/y, AT2+/y and DOCA-
salt, AT2−/y and DOCA-salt). RNA isolation from
homogenized kidneys, reverse transcription (RT), PCR
conditions, and quantification of gene expression analy-
sis with the ABI 5700 sequence detection system (ABI,
Darmstadt, Germany) for RT-PCR (TaqMan), and es-
pecially AT1 receptor gene expression were performed
as described [5]. Gene expression analysis for the NOS
genes were performed with 2 ng/lL cDNA equal to re-
verse transcribed RNA. The sequence of the mouse NOS
genes were derived from GenBank accession numbers
NM008712 (nNOS), NM008713 (eNOS), and AY090567
(iNOS). The sequence of primers and probes and the fi-
nal concentrations were: nNOS FP 5′-GAC TGA TGG
CAA GCA TGA CTT C-3′ (900 nmol/L), RP 5′-GCC
CAA GGT AGA GCC ATC TG-3′ (900 nmol/L), probe
5′ FAM-TGG AAC TCG CAG CTC ATC CGC TAT G-
TAMRA 3′ (100 nmol/L). eNOS FP 5′-TCT GCG GCG
ATG TCA CTA TG-3′ (900 nmol/L), RP 5′-CCA TGC
CGC CCT CTG TT-3′ (900 nmol/L), probe 5′ FAM-
AAC CAG CGT CCT GCA AAC CGT GC-TAMRA 3′
(150 nmol/L). iNOS FP 5′-TGA CGG CAA ACA TGA
CTT CAG-3′ (900 nmol/L), RP 5′-GCC ATC GGG CAT
CTG GTA-3′ (900 nmol/L), probe 5′ FAM-TGG AAT
TCA CAG CTC ATC CGG TAC GCT-TAMRA 3′ (200
nmol/L). Rodent glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was chosen as the endogenous control
(housekeeping gene). Results were evaluated per Taq-
Man plate. All data are given as mean ± SEM relative to
total mean.
For immunohistochemistry, the kidneys were washed
with ice-cold saline, blotted dry, weighed, frozen in
isopentane (−35◦C), and stored at −80◦C. Ice-cold
acetone-fixed cryosections (6 lm) were air dried and im-
mersed in 0.05 mol/L Tris buffer, 0.15 mol/L NaCl, pH 7.6
(TBS). All incubations were performed in a humid cham-
ber at room temperature. At first, the sections were incu-
bated in 10% normal donkey serum (Dianova, Germany)
for 30 minutes to block any nonspecific binding. The sec-
tions were incubated for 60 minutes with polyclonal iNOS
antibody (Santa Cruz, CA, USA). After washing with
TBS, the sections were incubated with Cy3-conjugated
secondary antibodies (donkey anti-rabbit IgG-Cy3; Di-
anova, Germany) for 60 minutes. After a final washing
with TBS, slides were mounted in Vectashield mounting
medium (Vector Laboratories, Burlingame, CA, USA).
Preparations were analyzed under a Zeiss Axioplan-2
microscope (Carl Zeiss, Jena, Germany), and digitally
photographed using AxioVision 2 multi channel image
processing system (Carl Zeiss).
Blood pressure
Blood pressure was measured by telemetry in four
AT2−/y mice and in five AT2 +/y mice. The mice were
anesthetized with isoflurane, and the left common carotid
artery was isolated. The catheter of the telemetric device
was inserted into the carotid artery below the bifurcation,
and advanced to the point where the small notch on the
tubing resided at the vessel opening so that the tip of the
catheter was placed inside of the thoracic aorta. After se-
curing the catheter at this position, the transmitter body
was placed into a subcutaneous pouch along the animal’s
right flank.
After seven to eight recovery days when normal
day/night rhythms of blood pressure and heart rate were
restored and the mice gained weight again, baseline val-
ues were continuously recorded for three days. There-
after, 50 mg DOCA tablets (Innovative Research of
America, Saratosa, FL, USA) were implanted, and the
mice were provided with 1% NaCl solution to drink [9,
10]. To characterize the effect of a selective inhibitor
of iNOS [11] on DOCA-salt induced blood pressure
changes, GED (Inotek Corp., Beverly, MA, USA) was
given in the third week of DOCA-salt. We chose this time
schedule because after two weeks of DOCA-salt, blood
pressure and sodium excretion does not increase further
[9]. GED 10 mg/kg intraperitoneally three times daily was
given over five days, and blood pressure measurements
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Fig. 1. Nitrite and nitrate (Nox) excretion before and after deoxycor-
ticosterone acetate (DOCA)-salt in AT2−/y and AT2+/y mice. NOx
excretory values represent the average of two 24-hour urine collections.
DOCA salt increased NOx excretion in both strains. ∗P < 0.05.
were continued (personal communication, Dr. G.
Southan, Inotek Corp.). All values were sampled every
five minutes for 10 seconds continuously day and night,
with a sampling rate of 1000 Hz. Values are shown as
24-hour means.
NOx measurements
In a subgroup of seven AT2−/y mice and nine AT2+/y
mice we verified that the urinary NOx excretion was ele-
vated by DOCA-salt treatment, as has been described
for rats [12]. The 24-hour urine collections were ob-
tained over two days after adaptation to the metabolic
cages (UNO Roestvaststaal; Zevenaar, The Nether-
lands). Urine was collected for NOx measurements un-
der baseline conditions and after DOCA-salt. Nitrite was
measured as a stable end product of NO using the Griess
reaction (CellTrend, Luckenwalde, Germany). Briefly,
150 lL diluted urine sample was incubated with 75 lL 1%
sulfanilamide and 75 lL 0,1% N-(1-naphthyl) ethylene-
diamine at room temperature. Nitrite content was mon-
itored spectrophotometrically at 520 nm and compared
with a sodium nitrite standard curve. Urinary NOx excre-
tion was calculated as NOx concentration multiplied by
urine volume.
Pressure-diuresis-natriuresis, renal blood flow,
glomerular filtration rate
To gain insight into the DOCA-salt–related effects,
we analyzed pressure-diuresis-natriuresis relationships,
RBF (AT2−/y: N = 10; AT2−/y and DOCA-salt: N =
8; AT2+/y: N = 10; AT2+/y and DOCA-salt: N = 6) and
GFR (AT2−/y: N = 8; AT2−/y and DOCA-salt: N =
12; AT2+/y: N = 7; AT2+/y and DOCA-salt: N =
10) in ketamine- (50 lg/g intraperitoneally, Parke-
AT2 –/y AT2 –/y
DOCA-salt
AT2 +/y AT2 +/y
DOCA-salt
0.4
0.8
1.2
1.6
e
N
O
S 
m
RN
A 
e
xp
re
ss
io
n,
ar
bi
tra
ry
 u
ni
ts
eNOS
AT2 –/y AT2 –/y
DOCA-salt
AT2 +/y AT2 +/y
DOCA-salt
0.4
0.8
1.2
1.6
n
N
O
S 
m
RN
A 
e
xp
re
ss
io
n,
ar
bi
tra
ry
 u
ni
ts
nNOS
* *
AT2 +/y AT2 +/y
DOCA-salt
AT2 –/y AT2 –/y
DOCA-salt
0.4
0.8
1.2
1.6
iN
O
S 
m
RN
A 
e
xp
re
ss
io
n,
ar
bi
tra
ry
 u
ni
ts
iNOS
*
*
*
*
Fig. 2. Renal gene expression of inducible nitric oxide synthase (iNOS)
(top), neuronal nitric oxide synthase (nNOS) (middle), and epithelial
nitric oxide synthase (eNOS) (bottom) in AT2−/y and AT2+/y mice
before and after deoxycorticosterone acetate (DOCA)-salt are shown.
iNOS and nNOS were up-regulated in AT2−/y mice. DOCA-salt in-
creased iNOS expression in both AT2−/y and AT2+/y mice. Renal
nNOS expression was only significantly decreased by DOCA-salt in
AT2−/y mice. Renal eNOS expression was not different between the
groups and not affected by DOCA-salt. ∗P< 0.05.
Davis GmBH, Berlin, Germany) and inaction- (100
lg/g intraperitoneally; Res Biochemical, Inc., Natick,
MA, USA) anesthetized mice. We relied on techniques
described earlier [3]. GFR was measured by inulin
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Fig. 3. Representative immunofluorescence staining of renal inducible nitric oxide synthase (iNOS) expression is presented. Deoxycorticosterone
acetate (DOCA)-salt–treated AT2−/y mice showed the highest iNOS expression within the glomerulus (red staining). DOCA-salt–treated AT2+/y
mice also showed more intense staining compared to the untreated control strains. Green fluorescence represents renal autofluorescence.
clearance, and RBF was determined using 0.5-mm V-
series flow probe (Transonic Systems, Inc., Ithaca, NY,
USA). After surgery and a 30- to 45-minute equilibra-
tion period, mean arterial pressure (MAP) and RBF were
recorded continuously, and urine was sampled in two
10- to 30-minute collecting periods. Renal perfusion pres-
sure (RPP) was then increased by tying off the mesen-
teric and celiac arteries, and thereafter by occluding the
aorta below the kidney. Blood pressure and renal blood
flow were calculated for each period by averaging all
recorded values during that time period. Renal vascu-
lar resistance (RVR) was calculated as the MAP-to-RBF
ratio. Urine was sampled and determined gravimetrically.
Urinary sodium concentrations were determined by ion-
selective electrode (Konelab Microlyte 3+2, Frankfurt,
Germany). Urine flow, sodium excretion (UNaV), GFR,
and RBF were normalized per gram kidney wet weight
(kwt).
2272 Obst et al: DOCA-salt in AT2 −/Y mice
AT2 –/y AT2 –/y
DOCA-salt
AT2 +/y AT2 +/y
DOCA-salt
0.0
0.5
1.0
1.5
AT
1 
re
ce
pt
or
 m
RN
A 
e
xp
re
ss
io
n,
ar
bi
tra
ry
 u
ni
ts
* *
Fig. 4. Angiotensin II type 1 receptor antagonist (AT1) receptor gene
expression in the kidneys of AT2+/y and AT2−/y mice with and without
deoxycorticosterone acetate (DOCA)-salt. The AT1 receptor was up-
regulated in AT2−/y mice. DOCA-salt decreased renal AT1 receptor
gene expression in AT2−/y mice. ∗P < 0.05.
Statistics
For statistical analysis, we relied on two-way analysis
of variance (ANOVA) and the Duncan test. Significance
was accepted at P < 0.05. Data are mean ± SEM.
RESULTS
We tested the relationship between the AT1 receptor
and NOS isoforms without concomitant AT2 receptor–
related effects under baseline conditions, and after
challenging the mice with DOCA-salt to stimulate NO
generation. Figure 1 shows 24-hour urinary NOx ex-
cretion before and after DOCA-salt treatment. Urinary
NOx levels in AT2+/y mice leveled at 16.40 ± 1.87 com-
pared with 9.4 ± 0.84 nmol/day in AT2−/y mice. In both
strains, urinary NOx excretion increased with DOCA-salt
to about 28 nmol/day. Thus, DOCA-salt administration
increased the NOx excretion.
Gene expression
The gene expression of renal NOS isoforms (nNOS,
iNOS, eNOS) is shown in Figure 2. Renal iNOS mRNA
was significantly higher in AT2−/y than in AT2 +/y mice
at 1.00 ± 0.05 versus 0.7 ± 0.07 arbitrary units, respec-
tively (upper panel). DOCA-salt increased the expres-
sion of renal iNOS (1.4 ± 0.10 vs. 1.0 ± 0.04 arbitrary
units) in AT2−/y and in AT2+/y mice significantly. Re-
nal nNOS expression was also increased in AT2−/y mice
compared with AT2+/y mice (1.5 ± 0.1 vs. 1.0 ± 0.1 arbi-
trary units). DOCA-salt decreased the nNOS mRNA val-
ues (middle panel) in AT2−/y mice; AT2+/y mice showed
a trend in the same direction. Renal eNOS expression
was not different between AT2−/y and AT2+/y mice, and
was not influenced by DOCA-salt (lower panel). Figure 3
shows that iNOS was found mainly in the glomeruli. The
highest signals were found with DOCA-salt treatment in
AT2−/y mice. These data suggest that iNOS and nNOS
genes were up-regulated in AT2−/y mice compared with
AT2+/y mice. iNOS gene expressions increased, and
nNOS expression decreased with DOCA-salt adminis-
tration. iNOS expression was most pronounced in the
glomeruli.
The renal AT1 receptor was up-regulated in AT2−/y
mice compared with AT2+/y mice (1.2 ± 0.07 vs. 0.9 ±
0.04 arbitrary units). DOCA-salt decreased the renal AT1
receptor gene expression slightly to 1.0 ± 0.07 arbitrary
units in AT2−/y mice to levels not different from AT2+/y
mice, as shown in Figure 4. These data suggest that the
AT1 receptor was up-regulated in AT2−/y mice, and that
DOCA-salt administration decreased AT1 receptor gene
expression when the AT2 receptor is absent.
Blood pressure
Figure 5 (upper panel) shows MAP in AT2−/y and
AT2+/y mice before and after DOCA-salt and the iNOS
inhibitor GED. MAP leveled at 123 ± 2 and at 114 ± 6 mm
Hg in AT2−/y and AT2+/y mice before DOCA-salt, and
increased significantly to 142 ± 3 and to 123 ± 7 mm
Hg, respectively. GED did not influence the blood pres-
sure levels in either strain. Figure 5 (lower panel) shows
the respective heart rates. Heart rates ranged between
566 and 588 beats/min in AT2−/y and AT2+/y mice be-
fore DOCA-salt, and decreased to about 500 beats/min as
blood pressure increased under DOCA-salt. As a reflec-
tion of the stronger increase in blood pressure, heart rate
decreased more in AT2−/y than in AT2+/y mice under
DOCA-salt. GED did not change these levels.
Pressure-diuresis-natriuresis, renal blood flow,
glomerular filtration rate
In untreated AT2+/y mice, urine flow and sodium ex-
cretion leveled at 23.94 ± 3.79 lL/min/g kwt and 4.48 ±
0.72 lmol/min/g kwt at a renal perfusion pressure (RPP)
level of 103 ± 2 mm Hg, respectively. Increasing RPP
to 141 ± 2 mm Hg increased urine flow and sodium
excretion to 109.24 ± 6.88 lL/min/g kwt and 19.63 ±
1.73 lmol/min/g kwt. At RPP levels of 107 and 147 mm
Hg, AT2−/y mice had urine flows and sodium excre-
tions of 19.56 ± 3.16 lL/min/g kwt and 3.40 ± 0.44 lmol/
min/g kwt, or 85.93 ± 7.63 lL/min/g kwt and 18.12 ±
1.62 lmol/min/g kwt, respectively. These values were re-
duced compared with AT2+/y mice. With DOCA-salt the
pressure-diuresis-natriuresis curves were shifted to the
right in AT2+/y and AT2−/y mice, as shown in Figure 6.
Figure 7 (upper panel) represents the effect of changing
RPP on RBF in AT2+/y mice and AT2−/y mice (lower
panel) with and without DOCA-salt. In all groups, RBF
was auto-regulated over the entire range of pressures.
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Fig. 5. Mean arterial pressure (MAP) (A)
and heart rate (B) in AT2−/y and AT2+/y
mice before and after deoxycorticosterone ac-
etate (DOCA)-salt and inducible nitric ox-
ide synthase (iNOS) inhibition by guanidi-
noethyldisulfide 2HCl (GED, 10 mg/kg, three
times a day, intraperitoneally) are shown.
MAP values were measured continuously
(24-hour) by telemetry. DOCA-salt increased
blood pressure stronger in AT2−/y mice than
in AT2+/y mice. GED did not change blood
pressure or heart rate levels. ∗P < 0.05.
RBF averaged, over the pressure range studied, 5.82 ±
0.33 mL/min/g kwt in AT2+/y mice, and 4.52 ± 0.31
mL/min/g kwt in AT2−/y mice, respectively. DOCA-salt
administration decreased RBF in AT2+/y mice to 4.43 ±
0.31 mL/min/g kwt, and in AT2−/y mice to a mean value
of 3.86 ± 0.18 mL/min/g kwt. The autoregulation in RBF
was caused by an increase in RVR, as RPP was increased
(data not shown). These data indicate that RBF was re-
duced in AT2−/y mice compared with AT2+/y mice, and
that DOCA-salt reduced RBF in AT2+/y and AT2−/y
mice. RVR reacted adequately in both strains to maintain
autoregulation of RBF in the pressure ranges studied.
Figure 8 (upper panel) shows the relationships between
RPP and GFR of AT2+/y and AT2−/y (lower panel)
mice with and without DOCA-salt. No significant GFR
differences were observed when AT2+/y and AT2−/y
mice were compared. GFR at all pressure levels averaged
1.10 ± 0.09 in AT2+/y, and 1.03 ± 0.09 mL/min g kidney wt
in AT2−/y mice, respectively. DOCA-salt decreased GFR
in both groups significantly. After DOCA-salt, GFR aver-
aged 0.76 ± 0.04 in AT2+/y mice and 0.72 ± 0.04 mL/min
g kidney wt in AT2−/y mice. These data show that GFR
was reduced by DOCA-salt in AT2−/y and AT2+/y mice.
DISCUSSION
We studied nNOS, iNOS, and eNOS, the three ma-
jor isoforms of NOS in AT2−/y mice with up-regulated
AT1 receptor expression. We challenged the mice with
DOCA-salt to increase NO production. We demon-
strated that in AT2−/y mice iNOS and nNOS were up-
regulated compared with AT2+/y mice. iNOS expression
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Fig. 6. Deoxycorticosterone acetate (DOCA)-salt treatment and the relationship between renal perfusion pressure and urine flow (left panel) and
sodium excretion (right panel) in AT2+/y mice (upper panels) and AT2−/y mice (lower panels). P < 0.05, values compared at equivalent renal
perfusion pressure levels. DOCA-salt shifted pressure natriuresis-diuresis curves toward right. ∗P < 0.05.
was further increased in both strains by DOCA-salt. With
immunohistochemistry, we found strong iNOS staining
in the glomeruli, especially after DOCA-salt in AT2−/y
mice. We observed little expression in other renal struc-
tures, which may be related in part to the antibody we
used. eNOS was not different between the strains and was
not affected by DOCA-salt. Concomitant blood pressure
values increased more in DOCA-salt–treated AT2−/y
mice compared with control mice. Pharmacologic iNOS
inhibition did not influence DOCA-salt blood pressures.
Pressure-natriuresis relationships shifted right in DOCA-
salt–treated mice. DOCA-salt reduced RBF and GFR in
AT2+/y mice and AT2−/y.
NO and NOS isoforms are important in the regula-
tion of cardiovascular and renal homeostasis. In the kid-
ney, NO regulates salt and fluid reabsorption, renal and
glomerular hemodynamics, tubuloglomerular feedback
responses, renin release, and renal sodium and water ex-
cretion [4]. NO and Ang II have many opposing effects
[13]. Strong evidence has been presented that the AT2
receptor mediates the renal production of NO in the rat
[14]. A role for nNOS was proposed. These data raised
the possibility that NOS expression might be decreased
in kidneys of AT2−/y mice. Such a decrease might ex-
plain their hypertension. However, this result did not ap-
pear to be the case. Instead, we found an up-regulation
of iNOS and nNOS in AT2−/y mice. These changes may
be a counter-regulatory reaction to the up-regulated AT1
receptor in these mice. Experiments with rat glomerular
mesangial cells have shown that Ang II dose dependently
inhibited iNOS mRNA and protein expression. The effect
was abolished by AT2 receptor blockade. On the other
hand, shifting the AT receptor expression toward the type
1 receptor led to an increased iNOS expression. These
experiments suggested that induced NO production was
enhanced by the AT1 receptor and diminished by the AT2
receptor [15]. The changes in AT1 receptor gene expres-
sion and/or altered NOS isoform expression may have
been involved in hemodynamic and functional changes
we described earlier for AT2−/y mice [3].
DOCA-salt increased blood pressure more in AT2−/y
mice than in AT2+/y mice. Our acute pressure-
natriuresis/diuresis experiments in AT2−/y and AT2+/y
mice confirmed earlier observations that DOCA-salt
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Fig. 7. Relationships between renal perfu-
sion pressure and renal blood flow in AT2+/y
(A) and in AT2−/y mice (B) with and with-
out deoxycorticosterone acetate (DOCA)-
salt. Renal blood flow was lower in AT2−/y
than in AT2+/y mice. DOCA-salt decreased
renal blood flow (RBF) in AT2+/y and in
AT2−/y mice. ∗P < 0.05. kwt is kidney wet
weight.
shifts these curves toward higher renal perfusion pres-
sures [16]. This shift to the right was accompanied by a
decrease in RBF and GFR and an increase in RVR. This
result underscores the crucial role of the kidney for long-
term blood pressure regulation [17].
An increase in salt intake increases NO production
and NO levels within the kidney [18, 19]. DOCA-
salt treatment results in an experimental form of
salt-dependent hypertension with increased urinary NOx
excretion [12]. Correspondingly, DOCA-salt administra-
tion also increased urinary NOx excretion in AT2−/y and
AT2+/y mice. Because the mice were not receiving a stan-
dardized NOx intake, and we did not measure plasma
NOx, the NOx excretion values should be interpreted
with caution. The method is relatively crude. We there-
fore did not concentrate on the relatively small differ-
ences in NOx excretion between AT2−/y and AT2+/y
mice, and did not correlate these values with the NOS
isoform expressions.
An up-regulation of eNOS and iNOS mRNA levels
has been reported earlier with DOCA-salt administra-
tion [12, 20]. We found no change in eNOS expression
after DOCA-salt. DOCA-salt induced an up-regulation
of iNOS. Immunohistochemistry confirmed strong iNOS
staining in the glomeruli, especially after DOCA-salt ad-
ministration in AT2−/y mice. We found little expression
in other renal structures, although we have not performed
confirmatory studies with Western blotting. In rats, iNOS
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Fig. 8. Deoxycorticosterone acetate (DOCA)-
salt and the relationship between renal perfusion
pressure and glomerular filtration rate (GFR) in
AT2+/y (A) and AT2−/y mice (B). DOCA-salt
decreased GFR inAT2+/y and AT2−/y mice.
∗P < 0.05. kwt is kidney wet weight.
was identified in renal vascular and tubular segments.
iNOS was implicated in sodium homeostasis as well as
in salt-induced hypertension [21, 22]. On the other hand,
an “interstitial” fraction of iNOS was described, which
may be proinflammatory [23]. Because pharmacologic
iNOS inhibition did not change blood pressure in AT2−/y
and AT2+/y DOCA-salt–treated mice, we believe that
the proinflammatory interstitial fraction of iNOS, and
not the tubular iNOS fraction that is involved in sodium
excretion, was up-regulated by DOCA-salt. GED iNOS
blockade in our AT2−/y and AT2+/y mice did not lower
blood pressure. This view agrees with experiments in
rats, in which application of aminoguanidine also did
not affect blood pressure [23, 24]. We suggest that for
hemodynamic and renal changes in our mice, AT1
receptor–dependent effects were more important than
effects related to changes in iNOS.
The focus of our study was not directed at end-organ
damage. Nevertheless, iNOS up-regulation may be rel-
evant in this setting [25]. The role of mineralocorticoid
receptor signaling in that regard is a topic of major in-
terest. DOCA-salt is known to stimulate nuclear factor
kappa B (NF-jB) signaling and the treatment stimu-
lates NAD(P)H oxidase [26]. Conceivably, we observed
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mechanisms by which DOCA-salt induces end-organ
damage. These mechanisms appear to have little or no
effect on blood pressure.
The AT1 receptor mediates Ang II–induced sodium
and water reabsorption in the renal tubules, and Ang II
is also involved in RBF regulation and tubuloglomerular
feedback responses, as well as in changes in renal intersti-
tial hydrostatic pressure [27–31]. The AT1 receptor is up-
regulated in AT2−/y mice. The up-regulation of the AT1
receptor in AT2−/y mice was found in various tissues and
seems to be a general phenomenon in these mice [3, 7, 8,
32]. The AT1 receptor response after DOCA-salt appears
to be quite variable. For hyper-mineralocorticoid states,
an up-regulation, no change, or a down-regulation of the
AT1 receptor were observed [9, 32–36]. The reasons for
these differences are not clear. They may depend on strain
differences or on the tissues examined. In our experi-
ments, DOCA-salt reduced renal AT1 receptor mRNA
in AT2−/y mice. Despite similar AT1 receptor expression
levels in AT2−/y and AT2+/y mice under DOCA-salt,
the Ang II–related effects may not be the same. AT2–/y
mice exhibit absence of AT2 receptor–related effects that
counter-regulate AT1 receptor–dependent Ang II effects.
CONCLUSION
We showed that the deletion of the AT2 receptor alone,
or with up-regulation of the AT1 receptor and the ad-
ministration of DOCA-salt, are strong stimuli for iNOS
induction. We suggest that up-regulation of iNOS is not
involved in hemodynamic changes caused by DOCA-salt.
iNOS inhibition did not affect blood pressure and heart
rate changes under DOCA-salt. Nevertheless, the iNOS
up-regulation may be related to subsequent organ dam-
age, a hypothesis worthy of testing.
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